Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. (Q41926865)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

title

Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

main subject

phase I clinical trial

0 references

1 reference

1 reference

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Elena Terletskaia-Ladwig

19

object named as

Elena Terletskaia-Ladwig

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

author name string

Karsten Geletneky

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Jacek Hajda

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Assia L Angelova

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Barbara Leuchs

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Andreas J Bartsch

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Jan-Oliver Neumann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Tilman Schöning

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Johannes Hüsing

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Birgit Beelte

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Irina Kiprianova

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Mandy Roscher

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Rauf Bhat

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Wolfgang Brück

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Alexandra Just

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Veronika Frehtman

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Stephanie Löbhard

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Jeremy Fry

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Karin Jochims

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Volker Daniel

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Ottheinz Krebs

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Michael Dahm

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Bernard Huber

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Andreas Unterberg

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Jean Rommelaere

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

David Capper

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

publication date

24 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

page(s)

2620-2634

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

31 March 2020

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5768665/fullTextXML

inferred from PubMed Central ID database lookup

cites work

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

7 January 2021

Oncolytic virotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

New viruses for cancer therapy: meeting clinical needs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Going viral with cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Parvoviruses: Small Does Not Mean Simple

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Attempts to isolate H-1 virus from spontaneous human abortions: a negative report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

H-1 VIRUS VIREMIA IN THE HUMAN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Double-faceted mechanism of parvoviral oncosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Oncolytic parvoviruses as cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

O10.04THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL SURVIVAL RESULTS AND QUALITY OF LIFE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Microglial secreted cathepsin B induces neuronal apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Microglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Induction of glioma apoptosis by microglia-secreted molecules: The role of nitric oxide and cathepsin B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Activation of a helper and not regulatory human CD4+ T cell response by oncolytic H-1 parvovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Response criteria for phase II studies of supratentorial malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Combined fluorescent in situ hybridization and immunofluorescence: limiting factors and a substitution strategy for slide-mounted tissue sections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

FISHing with locked nucleic acids (LNA): evaluation of different LNA/DNA mixmers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Fiji: an open-source platform for biological-image analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

NIH Image to ImageJ: 25 years of image analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Standardized large-scale H-1PV production process with efficient quality and quantity monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

Biochemical activities of minute virus of mice nonstructural protein NS1 are modulated In vitro by the phosphorylation state of the polypeptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2017.08.016

7 January 2021

inferred from DOI database lookup

Reciprocal productive and restrictive virus-cell interactions of immunosuppressive and prototype strains of minute virus of mice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28967558

12 December 2020

inferred from PubMed ID database lookup

Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28967558

12 December 2020

inferred from PubMed ID database lookup

Pathology, organ distribution, and immune response after single and repeated intravenous injection of rats with clinical-grade parvovirus H1

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28967558

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1016/J.YMTHE.2017.08.016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28967558%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference